Sidoti Csr Brokers Increase Earnings Estimates for Balchem

Balchem Co. (NASDAQ:BCPC - Free Report) - Equities researchers at Sidoti Csr lifted their FY2024 earnings per share estimates for shares of Balchem in a note issued to investors on Monday, October 28th. Sidoti Csr analyst K. May now expects that the basic materials company will post earnings per share of $4.36 for the year, up from their previous forecast of $4.11. The consensus estimate for Balchem's current full-year earnings is $3.96 per share. Sidoti Csr also issued estimates for Balchem's Q4 2024 earnings at $1.11 EPS.

Balchem (NASDAQ:BCPC - Get Free Report) last issued its quarterly earnings data on Friday, July 26th. The basic materials company reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.95 by $0.03. The firm had revenue of $234.08 million for the quarter, compared to analyst estimates of $241.26 million. Balchem had a return on equity of 10.94% and a net margin of 12.52%.

Other research analysts have also recently issued research reports about the company. HC Wainwright raised their target price on Balchem from $170.00 to $185.00 and gave the company a "buy" rating in a research note on Wednesday, July 31st. StockNews.com upgraded Balchem from a "hold" rating to a "buy" rating in a research note on Monday.

Balchem Stock Down 0.9 %

Shares of BCPC traded down $1.53 on Tuesday, reaching $169.26. The stock had a trading volume of 204,360 shares, compared to its average volume of 107,123. The firm has a market capitalization of $5.49 billion, a price-to-earnings ratio of 47.81, a price-to-earnings-growth ratio of 5.43 and a beta of 0.65. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.79 and a current ratio of 2.83. The company has a 50-day simple moving average of $171.75 and a 200-day simple moving average of $162.70. Balchem has a 12-month low of $113.90 and a 12-month high of $186.03.

Institutional Trading of Balchem

Several large investors have recently modified their holdings of BCPC. nVerses Capital LLC bought a new stake in shares of Balchem in the third quarter worth $35,000. Bessemer Group Inc. grew its holdings in shares of Balchem by 568.9% in the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company's stock worth $47,000 after acquiring an additional 256 shares during the period. GAMMA Investing LLC grew its holdings in shares of Balchem by 73.4% in the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company's stock worth $148,000 after acquiring an additional 356 shares during the period. Blue Trust Inc. grew its holdings in shares of Balchem by 642.5% in the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company's stock worth $148,000 after acquiring an additional 726 shares during the period. Finally, TD Asset Management Inc bought a new stake in shares of Balchem in the second quarter worth $200,000. Institutional investors own 87.91% of the company's stock.

Insider Buying and Selling at Balchem

In other news, SVP Gunsteren Job Leonard Van sold 7,750 shares of the business's stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $180.05, for a total value of $1,395,387.50. Following the completion of the transaction, the senior vice president now owns 8,540 shares in the company, valued at $1,537,627. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.25% of the stock is owned by company insiders.

Balchem Company Profile

Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.